John Anderson, MD
Ophthalmology · Houston, TXNPI 1891043147
Payments from drug & device makers
What this record shows
This record is dominated by food and beverage: $275 of the $326 with a category attached, or 84.5%. 7 manufacturers reported payments, led by Carl Zeiss Meditec, Inc. at 32.3% of the total. Reporting peaked in 2024 at $130 and has fallen 75.9% since, to $31 in 2025. That places this record below the midpoint for ophthalmology clinicians in TX, where the typical reported total is $1,835.
Across 10 payments — averaging $32.59 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.
- Carl Zeiss Meditec, Inc.$105
- Tarsus Pharmaceuticals, Inc.$80
- Biotissue Holdings Inc.$50
- Oyster Point Pharma, Inc.$31
- Shire North American Group Inc$27
- Alcon$19
- plus $14 from 1 others
What the payments were for
- Food & beverage$27585%
- Gifts$5015%
Most of this is food and beverage — typically meals provided during product presentations at a clinic or hospital. Nationally that is the single largest category of reported payments by count.
General payments by program year
Who reported the general payments
Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.
| Company | Payments | Total |
|---|---|---|
| Carl Zeiss Meditec, Inc. | 2 | $105 |
| Tarsus Pharmaceuticals, Inc. | 2 | $80 |
| Biotissue Holdings Inc. | 2 | $50 |
| Oyster Point Pharma, Inc. | 1 | $31 |
| Shire North American Group Inc | 1 | $27 |
| Alcon | 1 | $19 |
| Amgen | 1 | $14 |
How this compares
$326 in reported general payments places this provider in the 20th percentile of 1,355 ophthalmology providers in Texas.
Medicare billing
What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.
Most prescribed under Part D
| Drug | Claims | Cost to plans & patients |
|---|---|---|
| XiidraLifitegrast | 22 | $22,855 |
| VyzultaLatanoprostene Bunod | 22 | $7,348 |
| Prednisolone Acetate | 76 | $3,475 |
| Latanoprost | 213 | $1,616 |
| Dorzolamide-TimololDorzolamide Hcl/Timolol Maleat | 77 | $1,448 |
| MoxifloxacinMoxifloxacin Hcl | 72 | $1,299 |
| Ketorolac Tromethamine | 44 | $908 |
| Brimonidine Tartrate | 56 | $548 |
| Timolol Maleate | 62 | $380 |
| Neomycin-Polymyxin-DexamethNeomycin/Polymyxin B/Dexametha | 11 | $67 |
Paid to pharmacies, not to this prescriber.
Other ophthalmology in Houston
- John MichelettiHouston$916K
- Christina WengHouston$676K
- Peter ChangHouston$656K
- Zaina Al-MohtasebHouston$636K
- Stephen SladeHouston$530K
- David BrownHouston$514K
- Shaheen KavoussiHouston$480K
- Elvia CansecoHouston$322K
- Bac NguyenHouston$319K
- Douglas KochHouston$308K
Where these figures come from
- Payments: CMS Open Payments, program years 2019–2025 (publication P06302026_06032026).
- Billing: Medicare Physician & Other Practitioners, data year 2024. Original Medicare Part B only.
- Identity: NPPES NPI Registry, July 2026.